Histotype Px® Colorectal
Clinical decision support
The lack of reliable and affordable biomarkers to personalize treatment remains a major unsolved challenge in cancer, and in particular colorectal cancer (CRC). Surgery is the standard of care in stage II and stage III CRC, often followed by adjuvant chemotherapy (ACT) in a one-size-fits-all approach. However, most patients are cured by surgery alone in this indication and ACT provides no benefit to the majority of patients (96-98% in stage II and 80% in stage III), only exposing them to short- and long-term side effects. A personalized approach to ACT is therefore needed to avoid overtreatment of low-risk patients with reduced quality of life and unnecessary healthcare costs, and also to avoid undertreatment of early-stage cancers who in fact are high risk. The Histotype Px® Colorectal digital biomarker predicts the outcome for stage II and stage III CRC patients and can guide personalized treatment decisions for each patient identifying the patients who are likely to benefit from ACT and the patients who will do better without.
Video cover image by: Ketil Jordan
How was the Histotype Px® Colorectal biomarker developed?
Histotype Px® Colorectal* digital biomarker is an advanced deep neural network algorithm for determining recurrence and survival prognosis in colorectal cancer based on standard histology images. The colorectal algorithm is robust and based on solid ground truth and extensive training and testing with in total 4500 patient samples, 90 million image tiles. The slides were prepared at several sites, scanned at two sites with two different scanners, to ensure that the test is robust and can be used in clinical practice.
*The early version of Histotype Px® Colorectal was named DoMore-V1-CRC (and misc. variations of this description) during development in the DoMore! Project. The CE-IVD certified product Histotype Px® Colorectal is an updated version.
Video cover image: Marian Seiergren
AI and digital pathology will revolutionize the way we treat cancer
CEO and Co-Founder Torbjørn Furuseth presents the company and our leading digital biomarker Histotype Px® Colorectal at the LSX Nordic Congress 2023.
Technology
DoMore Diagnostics is a pioneer in utilizing artificial intelligence to increase the prognostic and predictive value of cancer tissue biopsies. The company’s AI-powered digital biomarker is based on extensive research at top universities with deep learning in histology image analysis. These new methods have resulted in fully automated histotyping that provide objective and precise prognostic information about patient outcomes. This novel histotyping can guide selection of therapy to avoid over- and undertreatment of cancer patients. It can also make cancer drug development more effective by ensuring more precise diagnosis and prognosis, which is the fundament for precision medicine.
Video cover image by: Ketil Jordan
Future Pipeline
DoMore Diagnostics is dedicated to expanding our potential and impact on improving cancer patients’ lives. We are actively pursuing further development and advancing our product portfolio for better outcome prediction and personalized cancer treatment.
Intellectual Property
DoMore Diagnostics has secured a global, exclusive license to the patents and patent applications covering the inventions.